Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy

被引:92
作者
Devillier, Raynier [1 ]
Coso, Diane [1 ]
Castagna, Luca [1 ,2 ]
Rossi, Isabelle Brenot [3 ]
Anastasia, Antonella [2 ]
Chiti, Arturo [4 ]
Ivanov, Vadim [1 ]
Schiano, Jean Marc [1 ]
Santoro, Armando [2 ]
Chabannon, Christian [1 ,5 ,6 ]
Balzarotti, Monica [2 ]
Blaise, Didier [1 ,5 ,6 ]
Bouabdallah, Reda [1 ]
机构
[1] Inst J Paoli I Calmettes, Dept Hematol, Transplantat & Cell Therapy Program, F-13009 Marseille, France
[2] Ist Clin Humanitas, Humanitas Canc Ctr, Hematol Unit, Milan, Italy
[3] Inst J Paoli I Calmettes, Dept Nucl Med, F-13009 Marseille, France
[4] Ist Clin Humanitas, Humanitas Canc Ctr, Nucl Med Unit, Milan, Italy
[5] Inst J Paoli I Calmettes, INSERM, CBT 510, Ctr Invest Clin Biotherapie, F-13009 Marseille, France
[6] Univ Aix Marseille, Fac Med, Inst J Paoli I Calmettes, Marseille, France
来源
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2012年 / 97卷 / 07期
关键词
Hodgkin's lymphoma; PET; outcome; relapsed refractory; ASCT; HIGH-DOSE CHEMOTHERAPY; PROGNOSTIC-FACTORS; FDG-PET; DISEASE; MULTICENTER; FAILURE; SCORE;
D O I
10.3324/haematol.2011.056051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background High-dose chemotherapy followed by autologous stem cell transplantation is the standard treatment for relapsed and/or refractory Hodgkin's lymphoma although half of patients relapse after transplantation. Predictive factors, such as relapse within 12 months, Ann-Arbor stage at relapse, and relapse in previously irradiated fields are classically used to identify patients with poor outcome. Recently, 18-fluorodeoxyglucose positron emission tomography has emerged as a new method for providing information to predict outcome. The aim of this study was to confirm the predictive value of positron emission tomography status after salvage therapy and to compare single versus tandem autologous stem cell transplantation in patients with relapsed and/or refractory Hodgkin's lymphoma. Design and Methods We report a series of 111 consecutive patients with treatment-sensitive relapsed and/or treatment-refractory Hodgkin's lymphoma who achieved complete (positron emission tomography-negative group) or partial remission (positron emission tomography-positive group) at positron emission tomography evaluation after salvage chemotherapy and who underwent single or tandem autologous stem cell transplantation. Results Five-year overall and progression-free survival rates were 81% and 64%, respectively. There were significant differences in 5-year progression-free survival (79% versus 23%; P<0.001) and 5-year overall survival (90% versus 55%, P=0.001) between the positron emission tomography-negative and -positive groups, respectively. A complete response, as determined by positron emission tomography evaluation, after salvage therapy predicted significantly better 5-year overall survival rates in both intermediate (91% versus 50%; P=0.029) and unfavorable (89% versus 58%; P=0.026) risk subgroup analyses. In the positron emission tomography-positive subgroup, tandem transplantation improved 5-year progression-free survival from 0% (in the single transplantation group) to 43% (P=0.034). Multivariate analysis showed that positron emission tomography status (hazard ratio: 5.26 [2.57-10.73]) and tandem transplantation (hazard ratio: 0.39 [0.19-0.78]) but not risk factors at relapse (hazard ratio: 1.77 [0.80-3.92]) significantly influenced progression-free survival, while only tomography status significantly influenced overall survival (hazard ratio: 4.03 [1.38-11.75]). Conclusions In patients with relapsed/refractory Hodgkin's lymphoma responding to prior salvage therapy, positron emission tomography response at time of autologous stem cell transplantation favorably influences outcome and enables identification of patients requiring single or tandem transplantation.
引用
收藏
页码:1073 / 1079
页数:7
相关论文
共 50 条
  • [41] Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents
    Pinto, Antonello
    Corradini, Paolo
    Mussetti, Alberto
    Zinzani, Pier Luigi
    LEUKEMIA & LYMPHOMA, 2015, 56 (07) : 1969 - 1974
  • [42] 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma
    Kahraman, Deniz
    Theurich, Sebastian
    Rothe, Achim
    Kuhnert, Georg
    Sasse, Stephanie
    Scheid, Christoph
    Dietlein, Markus
    Drzezga, Alexander
    von Bergwelt-Baildon, Michael
    Kobe, Carsten
    LEUKEMIA & LYMPHOMA, 2014, 55 (04) : 811 - 816
  • [43] Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution
    Shafer, J. A.
    Heslop, H. E.
    Brenner, M. K.
    Carrum, G.
    Wu, M. F.
    Liu, H.
    Ahmed, N.
    Gottschalk, S.
    Kamble, R.
    Leung, K. S.
    Myers, G. D.
    Bollard, C. M.
    Krance, R. A.
    LEUKEMIA & LYMPHOMA, 2010, 51 (04) : 664 - 670
  • [44] Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
    Younes, Anas
    Sureda, Anna
    Ben-Yehuda, Dina
    Zinzani, Pier Luigi
    Ong, Tee-Chuan
    Prince, H. Miles
    Harrison, Simon J.
    Kirschbaum, Mark
    Johnston, Patrick
    Gallagher, Jennifer
    Le Corre, Christophe
    Shen, Angela
    Engert, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (18) : 2197 - 2203
  • [45] High-dose chemotherapy and autologous stem-cell transplantation in Korean patients with relapsed or refractory Hodgkin lymphoma
    Kwonoh Park
    Dok Hyun Yoon
    Shin Kim
    Chan-Sik Park
    Jooryung Huh
    Sang-Wook Lee
    Cheolwon Suh
    International Journal of Hematology, 2013, 97 : 256 - 262
  • [46] A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation
    Tacyildiz, Nurdan
    Tanyildiz, Hikmet Gulsah
    Unal, Emel
    Dincaslan, Handan
    Asarcikli, Fikret
    Aksoy, Basak Adakli
    Vatansever, Goksel
    Yavuz, Gulsan
    TURKISH JOURNAL OF PEDIATRICS, 2019, 61 (05) : 671 - 676
  • [47] Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: A monocenter prospective study
    Castagna, Luca
    Magagnoli, Massimo
    Balzarotti, Monica
    Sarina, Barbara
    Siracusano, Licia
    Nozza, Andrea
    Todisco, Elisabetta
    Bramanti, Stefania
    Mazza, Rita
    Russo, Filippo
    Timofeeva, Inna
    Santoro, Armando
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (02) : 122 - 127
  • [48] Role of Consolidative Radiation Therapy After Autologous Hematopoietic Cell Transplantation for the Treatment of Relapsed or Refractory Hodgkin Lymphoma
    Wilke, Christopher
    Cao, Qing
    Dusenbery, Kathryn E.
    Bachanova, Veronika
    Lazaryan, Aleksandr
    Lee, Chung K.
    Yuan, Jianling
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (01): : 94 - 102
  • [49] The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma
    Moskowitz, CH
    Nimer, SD
    Glassman, JR
    Portlock, CS
    Yahalom, J
    Straus, DJ
    O'Brien, JP
    Elkin, N
    Bertino, JR
    Zelenetz, AD
    BONE MARROW TRANSPLANTATION, 1999, 23 (06) : 561 - 567
  • [50] Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation
    Ozuah, Nmazuo W.
    Dahmoush, Hisham M.
    Grant, Frederick D.
    Lehmann, Leslie E.
    LaCasce, Ann S.
    Billett, Amy L.
    Margossian, Steven P.
    PEDIATRIC BLOOD & CANCER, 2018, 65 (01)